Video

Dr. Mascarenhas on Limitations With JAK Inhibitors in Myelofibrosis

John O. Mascarenhas, MD, discusses limitations with JAK inhibitors in myelofibrosis.

John O. Mascarenhas, MD, associate professor of medicine, hematology, and medical oncology at the Icahn School of Medicine at Mount Sinai; director of the Adult Leukemia Program; and leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai, and a member of the Tisch Cancer Institute, discusses limitations with JAK inhibitors in myelofibrosis.

Myelofibrosis is a ​complex hematopoietic malignancy that often results in multiple hematologic events, including anemia, thrombocytopenia, increased blasts, transformation to acute leukemia, and spleen​/symptom burden, says Mascarenhas.

Notably, ​the JAK inhibitors ruxolitinib (Jakafi) and fedratinib (Inrebic) have been fundamental in treating certain aspects of the disease, such as spleen ailments​, Mascarenhas says. However, JAK inhibitors cannot treat anemia or ​alter the natural history of the disease.

As such, ongoing research efforts ​are evaluating a host of therapies that could potentially be used in the salvage setting for patients who progress on or are refractory to JAK inhibitors, Mascarenhas concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity